Brief: Aileron Therapeutics Presents Initial Findings From Ongoing Study Of ALRN-6924
27/08/2021 13:08
Aug 27 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS PRESENTS INITIAL FINDINGS FROM
ONGOING
HEALTHY VOLUNTEER STUDY OF ALRN-6924 AT ISEH 50TH ANNUAL
SCIENTIFIC MEETING
* AILERON THERAPEUTICS INC - INITIAL FINDINGS FROM AN
ONGOING
STUDY DEMONSTRATED THAT A 0.3 MG/KG DOSE OF ALRN-6924 HAS BEEN
VERY WELL TOLERATED
Source text for Eikon: ID:nGNX9JwXyM
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering